Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug reboot the immune system after a stem cell transplant?

NCT ID NCT05346809

Ongoing Disease control Sponsor: Divaya Bhutani Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus standard care. The study measures changes in immune cell counts and tracks side effects to see if the drug improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
isatuximab (Sarclisa) given intravenously alongside standard transplant procedures
What this could lead to
If it works, this could point toward a way to help the immune system fight blood cancers more effectively after a stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 8 participants, so results may not apply broadly. Isatuximab can cause infusion reactions and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma indolent B-cell non-Hodgkin lymphoma lymphoma mantle cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma non-Hodgkin lymphoma plasma cell myeloma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA MULTIPLE MYELOMA NON-HODGKIN LYMPHOMA RELAPSED HODGKIN'S DISEASE, ADULT

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.